Sharps Compliance Corp. (NASDAQ:SMED) (“Sharps” or the “Company”),
a leading full-service national provider of comprehensive waste
management solutions including medical, pharmaceutical and
hazardous, today reported financial results for the third quarter
and first nine months of fiscal 2017, which ended March 31, 2017.
Revenue in the third quarter of fiscal 2017
increased to $8.6 million, as compared to revenue of $6.7 million
in the same prior year quarter with improved gross margin of 27.4%
as compared to 25.5% in the third quarter of 2016. The
Company reported an operating loss of $0.6 million in the third
quarter of fiscal 2017, compared to an operating loss of $1.1
million in the third quarter of fiscal 2016. Sharps recorded
a net loss of $0.7 million, or ($0.04) per basic and diluted share
in the third quarter of fiscal 2017, compared to a net loss of $1.0
million or ($0.07) per basic and diluted share, in the third
quarter of fiscal 2016.
Customer billings increased 27% to $8.4 million for
the quarter ended March 31, 2017 as compared to billings of $6.6
million in the prior year period. The Company reported significant
growth in the Professional and Pharmaceutical Manufacturer markets
as well as growth in its Retail, Home Healthcare and Assisted
Living markets. Government market billings included $0.1 million of
orders under the VA’s Blanket Purchase Agreement and $0.2 million
of revenue from the MedSafe program. (See Reconciliation of
Customer Billings to Revenue in the supplemental table included at
the end of this release).
David P. Tusa, President and Chief Executive
Officer of Sharps, stated, “While quarterly revenue and SG&A
were consistent with or better than our internal forecasts, we do
believe we have opportunities to improve gross margin as our
treatment facilities increase the amount of mailbacks processed and
we continue to reduce operational costs.
“Revenue growth in the Professional and
Pharmaceutical Manufacturer markets was very strong, but overall
revenue growth was hampered by the second consecutive slow flu shot
immunization season.
“Our route-based business, which contributed 19% of
our third quarter billings, grew by over 160% driven by revenue
from our Citiwaste operation which was acquired in July of 2016.
The route-based business contributes stable revenue in markets
where proper disposal of medical waste is required by law,
complements our mailback offering and reduces the seasonal impact
of Retail market billings.”
Third Quarter Review
Professional market billings increased 49% to $3.0
million in the third quarter of fiscal 2017 compared to the prior
year period. This increase was a combination of acquired and
organic growth as the Company continued its focus on securing
customers from the small to medium quantity generator sector, which
consists largely of physicians, clinics, dentists, surgery centers,
veterinarians and other healthcare professionals, who benefit from
the cost-effective and convenient Sharps Recovery System™ and the
Company’s route-based pick-up services. The Company’s inside
and online sales channel, which primarily targets the Professional
and Government markets, realized a 45% increase in billings to $1.5
million in the fiscal 2017 third quarter from $1.0 million in the
same prior year period.
Pharmaceutical Manufacturer billings increased 35%
to $1.4 million in the third quarter of fiscal 2017 compared to
$1.0 million in the third quarter of fiscal 2016. The increase is
related to inventory builds for new and existing patient support
programs.
Retail market billings increased 11% to $0.8
million compared with $0.7 million in the prior year period,
reflecting a slight increase in flu shot related orders of about
$0.1 million.
Assisted Living market billings grew 8% to $0.6
million for the third quarter of fiscal 2017 as compared to $0.6
million in the third quarter of fiscal 2016. Third quarter
2017 Home Health Care billings grew 17% to $1.9 million as compared
to $1.6 million in the third quarter of the prior year.
Government billings were essentially flat at $0.4
million in the third quarter of fiscal 2017. Government
market billings included $0.1 million of orders under the VA’s
Blanket Purchase Agreement, consistent with $0.1 million in VA
orders in the third quarter of fiscal 2016. MedSafe related orders
to the government market were $0.2 million for the quarter ended
March 31, 2017, consistent with $0.2 million in the third quarter
of fiscal 2016.
Mr. Tusa added, “Our Professional market
demonstrated significant growth in the quarter, as a result not
only of our enhanced service offerings from our acquired
businesses, but also from the strength of our inside and field
sales teams who have been trained to find the best solution for
customers. Likewise, as expected, we saw solid growth in
Pharmaceutical Manufacturer market sales related to several
inventory builds in the quarter. Our unique solution for
Pharma companies ensures that medical waste compliance requirements
are met, provides a branding opportunity and the capability to
collect patient data which could lead to improved medication
adherence. Because of our vast experience with Pharmaceutical
Manufacturers, our ability to customize patient support programs
and collect and report valuable data, we believe we are uniquely
positioned as the leader in this market. We have seen increased
interest in the market for patient support programs from
manufacturers of new and existing self-injected medications.
“Additionally, we continue to see strong demand for
our MedSafe offering for the disposal of controlled and
non-controlled unused or expired medications. We believe we
are providing a valuable service to long-term care facilities,
retail and hospital pharmacies, hospice, drug-treatment and
licensed law enforcement markets with this patent-pending solution
addressing the nationwide concerns over opioid abuse and
environmental responsibility.”
Operating Performance
Gross margin was 27% in the third quarter of fiscal
2017 compared to gross margin of 26% in the third quarter of fiscal
2016. The increase in gross margin for the third quarter of fiscal
2017 was primarily related to increased revenue over the same
periods. SG&A increased slightly to $2.8 million for the third
quarter of fiscal 2017 compared to $2.7 million in the third
quarter of the prior year due to incremental sales and marketing
costs. Sequentially, SG&A is down $0.1 million, or 4%,
reflecting the impact of cost savings initiatives.
The Company reported an operating loss of $0.6
million in the third quarter of fiscal 2017, compared to an
operating loss of $1.1 million in the third quarter of fiscal
2016. Sharps EBITDA loss improved to $0.2 million in the
third quarter of fiscal 2017 as compared to an EBITDA loss of $0.9
million in the third quarter of fiscal 2016. (See Reconciliation of
Net Income (Loss) to EDITDA in the supplemental table included at
the end of this release).
Integration of Acquired Route-Based
Businesses and New Treatment Facility
During the third quarter of 2017, Sharps recognized
approximately $1.6 million in revenue from its route-based service
offering which represented about 19% of consolidated customer
revenue. For comparative purposes, the acquired businesses
generated $1.0 million of the $1.6 million in this quarterly
revenue based on their pre-acquisition run-rate with the difference
being attributable to organic growth.
As previously announced, during the second quarter
of 2017, the Company began operating its new medical waste
treatment facility in Pennsylvania. The facility operates as
both a medical waste treatment facility using an autoclave and as a
transfer station for medical, pharmaceutical and trace chemotherapy
waste of up to 82 tons per day. In addition to processing the
medical waste generated by the Company’s route-based and mailback
customers, the facility also serves as an outbound distribution
center of mailbacks and other solutions.
First Nine Months Fiscal 2017
Review
Sharps recorded revenue of $27.8 million in the
first nine months of fiscal 2017, an increase of 14% compared to
revenue of $24.5 million in the first nine months of fiscal
2016. Customer billings increased 10% to $27.5 million in the
first nine months of fiscal 2017. Professional billings
increased 58% to $8.8 million in the first nine months of fiscal
2017 as compared to $5.6 million in the same prior year period.
Assisted Living billings increased 10% to $1.8 million in the first
nine months of fiscal 2017 as compared to $1.6 million in the same
prior year period. Government billings increased 10% to $1.2
million in the first nine months of fiscal 2017 as compared to $1.1
million in the same prior year period. Pharmaceutical Manufacturer
billings decreased 4% to $4.6 million in the first nine months of
fiscal 2017 as compared to $4.8 million in the first nine months of
2016. Home Health Care billings increased slightly to $5.8
million in the first nine months of fiscal 2017 as compared to $5.6
million in the same prior year period. In the first nine
months of fiscal 2017, Retail billings declined 18% to $4.5 million
as compared to $5.5 million in the first nine months of fiscal
2016, primarily due to a decrease in billings for the TakeAway
Medication Recovery System envelopes which were launched by several
Retail customers in the prior year. Billings for the flu shot
related business were relatively flat for the first nine months of
fiscal 2017 compared to the prior year. On a trailing twelve
months’ basis, flu shot related business in the Retail market
increased 10% in the current period compared to the prior
year.
Fiscal 2017 year-to-date gross margin was 30% as
compared to gross margin of 32% in the first nine months of fiscal
2016. SG&A expense increased 19% to $9.4 million in the
first nine months of fiscal 2017. SG&A for the first nine
months of fiscal 2017 includes $0.7 million of acquisition related
costs. Without these acquisition related costs, SG&A
increased 10% compared to the first nine months of fiscal 2016 as a
result of the Company's ongoing investment in sales and marketing
initiatives. The Company recorded an operating loss of $1.8
million in the first nine months of fiscal 2017 as compared to an
operating loss $0.2 million in the first nine months of fiscal
2016.
Net loss in the first nine months of fiscal 2017
was $1.9 million or ($0.12) per basic and diluted share, compared
to net loss of $0.2 million or ($0.01) per basic and diluted share
in the first nine months of fiscal 2016. During the
first nine months of 2017, the Company recorded approximately $0.7
million in acquisition related expenses associated with the
completion of its acquisition of Citiwaste. Excluding these
acquisition related expenses, on a non-GAAP basis, the Company
reported an adjusted net loss of $1.2 million or ($0.07) per
diluted share in the first nine months of 2017. (See Reconciliation
of Net Income (Loss) to Adjusted Net Income (Loss) in the
supplemental table included at the end of this release).
Financial Flexibility and a Strong Balance
Sheet
Cash and cash equivalents were $5.7 million at
March 31, 2017 compared to $12.4 million at June 30, 2016.
The decrease in cash and cash equivalents is primarily due to the
$4.0 million paid for the Citiwaste acquisition, payment of
acquisition related costs, and capital expenditures, including
those related to the new Pennsylvania treatment facility.
On March 29, 2017, the Company entered into a
credit agreement with a commercial bank (“Credit
Agreement”). The Credit Agreement, which replaces, in
its entirety, the Company’s prior credit agreement with
another commercial bank, provides for a two-year, $14.0 million
line of credit facility, the proceeds of which may be utilized as
follows: (i) $6.0 million for working capital, letters of credit
(up to $2 million) and general corporate purposes and (ii) $8.0
million for acquisitions.
Expanding Capabilities: A Comprehensive
Provider of Medical Waste Service Solutions
Mr. Tusa concluded, “As we continue to enhance our
portfolio of comprehensive medical and pharmaceutical waste
management solutions, we believe we are well positioned to build on
our customer base in the underserved small to medium quantity
generator market. We plan to continue to expand the
geographic reach of our route-based offering which complements our
convenient mailback solutions to meet the needs of our existing
customers and to win new business.”
Third Quarter Fiscal Year 2017 Webcast and
Conference Call
The Company will host a teleconference today
beginning at 11:00 a.m. Eastern Time, during which management will
review the financial and operating results for the period and
discuss Sharps’ corporate strategy and outlook. A
question-and-answer session will follow.
The Sharps conference call can be accessed by
domestic callers by dialing (877) 407-0782. International
callers may access the call by dialing (201) 689-8567. The
webcast can be monitored at
www.sharpsinc.com.
A telephonic replay will be available through May
26, 2017. To listen to the replay, domestic callers should
dial (877) 481-4010 and international callers should dial (919)
882-2331 and enter replay ID number 10333. Transcript will also be
posted to the Sharps website, once available.
About Sharps Compliance Corp.
Headquartered in Houston, Texas, Sharps Compliance
is a leading full-service national provider of comprehensive waste
management services including medical, pharmaceutical and
hazardous. Its key markets include healthcare facilities,
pharmaceutical manufacturers, home healthcare providers, assisted
living / long-term care, surgery centers, retail pharmacies and
clinics, and the professional market which is comprised of
physicians, dentists and veterinary practices. The Company's
flagship product, the Sharps Recovery System, is a comprehensive
solution for the containment, transportation, treatment and
tracking of medical waste and other used healthcare materials. The
Company also offers its route-based pick-up service in a twelve
(12) state region of the Northeast portion of the United States as
well as Texas and Louisiana.
More information on the Company and its products
can be found on its website at: www.sharpsinc.com
Safe Harbor Statement
The information made available in this news release
contains certain forward-looking statements which reflect Sharps
Compliance Corp.’s current view of future events and financial
performance. Wherever used, the words “estimate,” “expect,”
“plan,” “anticipate,” “believe,” “may” and similar expressions
identify forward-looking statements. Any such forward-looking
statements are subject to risks and uncertainties and the Company’s
future results of operations could differ materially from
historical results or current expectations. Some of these
risks include, without limitation, the Company’s ability to educate
its customers, development of public awareness programs to educate
the identified consumer, customer preferences, the Company’s
ability to scale the business and manage its growth, the degree of
success the Company has at gaining more large customer contracts,
managing regulatory compliance and/or other factors that may be
described in the Company’s annual report on Form 10-K, quarterly
reports on Form 10-Q and/or other filings with the Securities and
Exchange Commission. Future economic and industry trends that
could potentially impact revenue and profitability are difficult to
predict. The Company assumes no obligation to publicly update
or revise its forward-looking statements even if experience or
future changes make it clear that any projected results, express or
implied therein, will not be realized.
Non-GAAP Measures
This release contains certain financial information
not derived in accordance with generally accepted accounting
principles (“GAAP”), including customer billings information,
EBITDA and non-GAAP net income per share. The Company believes this
information is useful to investors and other interested parties.
EBITDA is a significant performance metric used by management and
by external users of our financial statements such as investors,
research analysts and others to assess the financial performance of
our assets without regard to financing methods, capital structure
or historical cost basis; the ability of our assets to generate
cash sufficient to pay interest costs and support our indebtedness;
and our operating performance and return on capital as compared to
those of other companies in our industry. Such information should
not be considered as a substitute for any measure derived in
accordance with GAAP, and may not be comparable to other similarly
titled measures of other companies. Reconciliation of this
information to the most comparable GAAP measures is included as an
attachment to this release.
FINANCIAL TABLES FOLLOW
Sharps Compliance Corp. and
Subsidiaries |
Condensed Consolidated Statements of
Operations |
(in thousands, except per share
data) |
(Unaudited) |
|
|
Three-Months Ended |
|
Nine-Months Ended |
|
|
March 31, |
|
March 31, |
|
|
|
2017 |
|
|
|
2016 |
|
% Change |
|
2017 |
|
|
|
2016 |
|
% Change |
|
|
|
|
|
|
|
|
|
Revenue |
$ |
8,588 |
|
|
$ |
6,652 |
|
29.1 |
% |
$ |
27,826 |
|
|
$ |
24,513 |
|
13.5 |
% |
Cost of
revenue |
|
6,236 |
|
|
|
4,959 |
|
25.8 |
% |
|
19,620 |
|
|
|
16,622 |
|
18.0 |
% |
Gross
profit |
|
2,352 |
|
|
|
1,693 |
|
38.9 |
% |
|
8,206 |
|
|
|
7,891 |
|
4.0 |
% |
Gross
margin |
|
27.4 |
% |
|
|
25.5 |
% |
|
|
29.5 |
% |
|
|
32.2 |
% |
|
SG&A
expense |
|
2,790 |
|
|
|
2,709 |
|
3.0 |
% |
|
9,388 |
|
|
|
7,890 |
|
19.0 |
% |
Depreciation and amortization |
|
200 |
|
|
|
88 |
|
|
|
600 |
|
|
|
210 |
|
|
Operating
loss |
|
(638 |
) |
|
|
(1,104 |
) |
|
|
(1,782 |
) |
|
|
(209 |
) |
|
Operating
margin |
|
(7.4 |
%) |
|
|
(16.6 |
%) |
|
|
(6.4 |
%) |
|
|
(0.9 |
%) |
|
Interest
income |
|
4 |
|
|
|
8 |
|
|
|
12 |
|
|
|
26 |
|
|
Interest
expense |
|
(34 |
) |
|
|
- |
|
|
|
(92 |
) |
|
|
- |
|
|
Total
other (expense) income |
|
(30 |
) |
|
|
8 |
|
|
|
(80 |
) |
|
|
26 |
|
|
Loss before income tax
expense (benefit) |
|
(668 |
) |
|
|
(1,096 |
) |
|
|
(1,862 |
) |
|
|
(183 |
) |
|
Income tax expense
(benefit) |
|
- |
|
|
|
(54 |
) |
|
|
- |
|
|
|
24 |
|
|
Net
loss |
$ |
(668 |
) |
|
$ |
(1,042 |
) |
|
$ |
(1,862 |
) |
|
$ |
(207 |
) |
|
Net loss per
share |
|
|
|
|
|
|
|
|
Basic and
Diluted |
$ |
(0.04 |
) |
|
$ |
(0.07 |
) |
|
$ |
(0.12 |
) |
|
$ |
(0.01 |
) |
|
|
|
|
|
|
|
|
|
|
Weighted
Average Shares Outstanding |
|
|
|
|
|
|
|
|
Basic and Diluted |
|
15,994 |
|
|
|
15,462 |
|
|
|
15,930 |
|
|
|
15,449 |
|
|
|
|
|
|
|
|
|
|
|
Sharps Compliance Corp. and
Subsidiaries |
Condensed Consolidated Balance
Sheets |
(in thousands) |
(Unaudited) |
|
|
March 31, 2017 |
|
June 30, 2016 |
ASSETS: |
|
|
|
Current assets: |
|
|
|
Cash and
cash equivalents |
$ |
5,692 |
|
$ |
12,435 |
Accounts
receivable, net |
|
5,191 |
|
|
5,814 |
Inventory |
|
4,526 |
|
|
3,919 |
Prepaid
and other current assets |
|
853 |
|
|
695 |
Total
current assets |
|
16,262 |
|
|
22,863 |
Property, plant and
equipment, net |
|
6,756 |
|
|
5,032 |
Other assets |
|
118 |
|
|
84 |
Goodwill |
|
6,724 |
|
|
1,039 |
Intangible assets,
net |
|
4,162 |
|
|
1,129 |
Total
assets |
$ |
34,022 |
|
$ |
30,147 |
|
|
|
|
|
|
|
|
LIABILITIES AND
STOCKHOLDERS' EQUITY: |
|
|
|
Current
liabilities: |
|
|
|
Accounts
payable |
$ |
2,469 |
|
$ |
1,620 |
Accrued
liabilities |
|
1,340 |
|
|
1,534 |
Current
maturities of long-term debt |
|
604 |
|
|
- |
Deferred
revenue |
|
2,223 |
|
|
2,477 |
Total
current liabilities |
|
6,636 |
|
|
5,631 |
Long-term deferred
revenue, net of current portion |
|
498 |
|
|
483 |
Other long-term
liabilities |
|
166 |
|
|
190 |
Long-term debt, net of
current portion |
|
2,121 |
|
|
- |
Total
liabilities |
|
9,421 |
|
|
6,304 |
Stockholders'
equity |
|
24,601 |
|
|
23,843 |
Total
liabilities and stockholders' equity |
$ |
34,022 |
|
$ |
30,147 |
|
|
|
|
Sharps Compliance Corp. and
Subsidiaries |
Supplemental Customer Billing and Revenue
Information |
(in thousands) |
(Unaudited) |
|
|
|
Three-Months Ended March 31, |
|
|
|
2017 |
|
% Total |
|
|
2016 |
|
|
$ Change |
|
% |
BILLINGS BY
MARKET: |
|
|
|
|
|
|
|
|
|
|
Professional |
|
$ |
2,982 |
|
35.4 |
% |
|
$ |
2,001 |
|
|
$ |
981 |
|
|
49.0 |
% |
Home
Health Care |
|
|
1,873 |
|
22.2 |
% |
|
|
1,595 |
|
|
|
278 |
|
|
17.4 |
% |
Pharmaceutical Manufacturer |
|
|
1,377 |
|
16.3 |
% |
|
|
1,023 |
|
|
|
354 |
|
|
34.6 |
% |
Retail |
|
|
806 |
|
9.6 |
% |
|
|
726 |
|
|
|
80 |
|
|
11.0 |
% |
Assisted
Living |
|
|
625 |
|
7.4 |
% |
|
|
579 |
|
|
|
46 |
|
|
7.9 |
% |
Government |
|
|
424 |
|
5.0 |
% |
|
|
423 |
|
|
|
1 |
|
|
0.2 |
% |
Environmental |
|
|
149 |
|
1.8 |
% |
|
|
70 |
|
|
|
79 |
|
|
112.9 |
% |
Other |
|
|
195 |
|
2.3 |
% |
|
|
201 |
|
|
|
(6 |
) |
|
(3.0 |
%) |
Subtotal |
|
$ |
8,431 |
|
100.0 |
% |
|
$ |
6,618 |
|
|
$ |
1,813 |
|
|
27.4 |
% |
GAAP
Adjustment * |
|
|
157 |
|
|
|
|
34 |
|
|
|
123 |
|
|
|
Revenue
Reported |
|
$ |
8,588 |
|
|
|
$ |
6,652 |
|
|
$ |
1,936 |
|
|
29.1 |
% |
|
|
|
|
|
|
|
|
|
|
|
|
|
Nine-Months Ended March 31, |
|
|
|
2017 |
|
% Total |
|
|
2016 |
|
|
$ Change |
|
% |
BILLINGS BY
MARKET: |
|
|
|
|
|
|
|
|
|
|
Professional |
|
$ |
8,817 |
|
32.0 |
% |
|
$ |
5,573 |
|
|
$ |
3,244 |
|
|
58.2 |
% |
Home
Health Care |
|
|
5,760 |
|
20.9 |
% |
|
|
5,637 |
|
|
|
123 |
|
|
2.2 |
% |
Pharmaceutical Manufacturer |
|
|
4,568 |
|
16.6 |
% |
|
|
4,777 |
|
|
|
(209 |
) |
|
(4.4 |
%) |
Retail |
|
|
4,507 |
|
16.4 |
% |
|
|
5,512 |
|
|
|
(1,005 |
) |
|
(18.2 |
%) |
Assisted
Living |
|
|
1,789 |
|
6.5 |
% |
|
|
1,623 |
|
|
|
166 |
|
|
10.2 |
% |
Government |
|
|
1,245 |
|
4.4 |
% |
|
|
1,129 |
|
|
|
116 |
|
|
10.3 |
% |
Environmental |
|
|
291 |
|
1.1 |
% |
|
|
224 |
|
|
|
67 |
|
|
29.9 |
% |
Other |
|
|
567 |
|
2.1 |
% |
|
|
651 |
|
|
|
(84 |
) |
|
(12.9 |
%) |
Subtotal |
|
$ |
27,544 |
|
100.0 |
% |
|
$ |
25,126 |
|
|
$ |
2,418 |
|
|
9.6 |
% |
GAAP
Adjustment * |
|
|
282 |
|
|
|
|
(613 |
) |
|
|
895 |
|
|
|
Revenue
Reported |
|
$ |
27,826 |
|
|
|
$ |
24,513 |
|
|
$ |
3,313 |
|
|
13.5 |
% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
*
Represents the net impact of the revenue recognition adjustments to
arrive at reported GAAP revenue. Customer billings include all
invoiced amounts for products shipped during the period reported.
GAAP revenue includes customer billings as well as numerous
adjustments necessary to reflect, (i) the deferral of a portion of
current period sales and (ii) recognition of certain revenue
associated with product returned for treatment and destruction. The
difference between customer billings and GAAP revenue is reflected
in the Company’s balance sheet as deferred revenue. |
Sharps Compliance Corp. and
Subsidiaries |
Supplemental Customer Billing by Solution
Information |
(in thousands) |
(Unaudited) |
|
|
|
Three-Months Ended March 31, |
|
|
|
2017 |
|
% Total |
|
|
2016 |
|
$ Change |
|
% |
BILLINGS BY SOLUTION: |
|
|
|
|
|
|
|
|
|
Mailbacks |
$ |
4,840 |
|
57.4 |
% |
|
$ |
4,274 |
|
$ |
566 |
|
|
13.2 |
% |
Route-Based Pickup |
|
1,641 |
|
19.5 |
% |
|
|
628 |
|
|
1,013 |
|
|
161.3 |
% |
Unused Medications |
|
867 |
|
10.3 |
% |
|
|
707 |
|
|
160 |
|
|
22.6 |
% |
Third Party Treatment |
|
149 |
|
1.8 |
% |
|
|
70 |
|
|
79 |
|
|
112.9 |
% |
Other |
|
|
934 |
|
11.0 |
% |
|
|
939 |
|
|
(5 |
) |
|
(0.5 |
%) |
Total Billings By Solution |
$ |
8,431 |
|
100.0 |
% |
|
$ |
6,618 |
|
$ |
1,813 |
|
|
27.4 |
% |
|
|
|
|
|
|
|
|
|
|
|
|
|
Nine-Months Ended March 31, |
|
|
|
2017 |
|
% Total |
|
|
2016 |
|
$ Change |
|
% |
BILLINGS BY SOLUTION: |
|
|
|
|
|
|
|
|
|
Mailbacks |
$ |
17,379 |
|
63.1 |
% |
|
$ |
17,859 |
|
$ |
(480 |
) |
|
(2.7 |
%) |
Route-Based Pickup |
|
4,686 |
|
17.0 |
% |
|
|
1,469 |
|
|
3,217 |
|
|
219.0 |
% |
Unused Medications |
|
2,400 |
|
8.7 |
% |
|
|
2,743 |
|
|
(343 |
) |
|
(12.5 |
%) |
Third Party Treatment |
|
291 |
|
1.1 |
% |
|
|
224 |
|
|
67 |
|
|
29.9 |
% |
Other |
|
|
2,788 |
|
10.1 |
% |
|
|
2,831 |
|
|
(43 |
) |
|
(1.5 |
%) |
Total Billings By Solution |
$ |
27,544 |
|
100.0 |
% |
|
$ |
25,126 |
|
$ |
2,418 |
|
|
9.6 |
% |
Sharps Compliance Corp. and
Subsidiaries |
Supplemental Customer Billing by Channel
Information |
(in thousands) |
(Unaudited) |
|
|
|
Three-Months Ended March 31, |
|
|
|
2017 |
|
% Total |
|
2016 * |
|
$ Change |
|
% Change |
BILLINGS BY
CHANNEL: |
|
|
|
|
|
|
|
|
|
|
Direct
Sales |
|
$ |
4,475 |
|
53.1 |
% |
|
$ |
3,402 |
|
$ |
1,073 |
|
|
31.5 |
% |
Distributors |
|
|
2,457 |
|
29.1 |
% |
|
|
2,181 |
|
|
276 |
|
|
12.7 |
% |
Inside
and Online Sales |
|
|
1,499 |
|
17.8 |
% |
|
|
1,035 |
|
|
464 |
|
|
44.7 |
% |
Total
Billings By Channel |
|
$ |
8,431 |
|
100.0 |
% |
|
$ |
6,618 |
|
$ |
1,813 |
|
|
27.4 |
% |
|
|
|
|
|
|
|
|
|
|
|
|
|
Nine-Months Ended March 31, |
|
|
|
2017 |
|
% Total |
|
2016 * |
|
$ Change |
|
% Change |
BILLINGS BY
CHANNEL: |
|
|
|
|
|
|
|
|
|
|
Direct
Sales |
|
$ |
15,142 |
|
55.0 |
% |
|
$ |
13,725 |
|
$ |
1,417 |
|
|
10.3 |
% |
Distributors |
|
|
7,513 |
|
27.3 |
% |
|
|
8,339 |
|
|
(826 |
) |
|
(9.9 |
%) |
Inside
and Online Sales |
|
|
4,889 |
|
17.7 |
% |
|
|
3,062 |
|
|
1,827 |
|
|
59.6 |
% |
Total
Billings By Channel |
|
$ |
27,544 |
|
100.0 |
% |
|
$ |
25,126 |
|
$ |
2,418 |
|
|
9.6 |
% |
|
* Certain
prior year amounts have been reclassified to conform to current
year presentation |
Sharps Compliance Corp. and
Subsidiaries |
Supplemental Table to Reconcile Net Income
(Loss) to EBITDA |
(in thousands) |
(Unaudited) |
|
|
Three-Months Ended |
|
Nine-Months Ended |
|
March 31, |
|
March 31, |
|
|
2017 |
|
|
|
2016 |
|
|
|
2017 |
|
|
|
2016 |
|
|
|
|
|
|
|
|
|
Net
Loss |
$ |
(668 |
) |
|
$ |
(1,042 |
) |
|
$ |
(1,862 |
) |
|
$ |
(207 |
) |
|
|
|
|
|
|
|
|
Income
tax expense (benefit) |
|
- |
|
|
|
(54 |
) |
|
|
- |
|
|
|
24 |
|
Interest
expense (income), net |
|
30 |
|
|
|
(8 |
) |
|
|
80 |
|
|
|
(26 |
) |
Depreciation and amortization |
|
392 |
|
|
|
223 |
|
|
|
1,100 |
|
|
|
601 |
|
|
|
|
|
|
|
|
|
EBITDA |
$ |
(246 |
) |
|
$ |
(881 |
) |
|
$ |
(682 |
) |
|
$ |
392 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
The
Company defines earnings before interest, taxes, depreciation and
amortization (“EBITDA”) as net income (loss), plus income tax
expense, interest income, and depreciation and amortization.
Other companies may define EBITDA differently. EBITDA is presented
because it is a financial measure that is frequently requested by
third parties. However, EBITDA is not considered under
generally accepted accounting principles as a primary measure of an
entity’s financial results, and accordingly, EBITDA should
not be considered an alternative to operating income, net income,
or cash flows as determined under generally accepted accounting
principles and as reported by the Company. |
Sharps Compliance Corp. and
Subsidiaries |
Supplemental Reconciliation of GAAP to
Non-GAAP Net Income (Loss) Per Share* |
(in thousands, except per share
data) |
(Unaudited) |
|
|
|
Three-Months Ended |
|
Nine-Months Ended |
|
|
March 31, |
|
March 31, |
|
|
|
2017 |
|
|
|
2016 |
|
|
|
2017 |
|
|
|
2016 |
|
|
|
|
|
|
|
|
|
|
Net
Loss |
|
$ |
(668 |
) |
|
$ |
(1,042 |
) |
|
$ |
(1,862 |
) |
|
$ |
(207 |
) |
|
|
|
|
|
|
|
|
|
Diluted net loss per share |
|
$ |
(0.04 |
) |
|
$ |
(0.07 |
) |
|
$ |
(0.12 |
) |
|
$ |
(0.01 |
) |
|
|
|
|
|
|
|
|
|
Adjustments: |
|
|
|
|
|
|
|
|
Acquisition costs |
|
|
- |
|
|
|
- |
|
|
|
702 |
|
|
|
151 |
|
|
|
|
|
|
|
|
|
|
Adjustments |
|
|
- |
|
|
|
- |
|
|
|
702 |
|
|
|
151 |
|
|
|
|
|
|
|
|
|
|
Adjusted Net
Loss |
|
$ |
(668 |
) |
|
$ |
(1,042 |
) |
|
$ |
(1,160 |
) |
|
$ |
(56 |
) |
|
|
|
|
|
|
|
|
|
Adjusted diluted net loss per share |
|
$ |
(0.04 |
) |
|
$ |
(0.07 |
) |
|
$ |
(0.07 |
) |
|
$ |
(0.00 |
) |
|
|
|
|
|
|
|
|
|
* In
accordance with U.S. generally accepted accounting principles
(GAAP), the Company’s net deferred tax assets have been fully
reserved by a tax valuation allowance and any tax expense (benefit)
has been offset by the utilization of net operating loss
carryforwards or additional deferred tax valuation allowance.
Therefore, the amounts shown in this schedule have not been
adjusted to reflect any tax impact. The Company defines adjusted
net income as net income plus or minus certain nonrecurring
transactions such as acquisition costs, executive severance costs,
significant legal settlements and other interested parties.
Such information would not be considered as a substitute for any
measure derived in accordance with GAAP, and may not be comparable
to other similarly titled measures of other companies. |
For more information contact:
Diana P. Diaz
Sharps Compliance Corp.
Vice President and Chief Financial Officer
Phone: (713) 660-3547
Email: ddiaz@sharpsinc.com
John Nesbett/Jennifer Belodeau
Institutional Marketing Services (IMS)
Phone: (203) 972-9200
Email: jnesbett@institutionalms.com
Sharps Compliance (NASDAQ:SMED)
Historical Stock Chart
From Mar 2024 to Apr 2024
Sharps Compliance (NASDAQ:SMED)
Historical Stock Chart
From Apr 2023 to Apr 2024